Art Unit 2894
Group 2890Semiconductors B
- Active examiners
- 21
- Average office actions per grant
- 1.88
Grant ratio
- Art Unit 2894
- 78.0%
- Group 2890
- 72.0%
Active examiners
| Caleb Henry | 84.7% | 1.65 | October 2026 |
|---|---|---|---|
| Jami M. Valentine | 94.1% | 1.32 | October 2026 |
| Duy T. Nguyen | 76.3% | 2.29 | October 2026 |
| Timor Karimy | 80.5% | 1.95 | October 2026 |
| Brook Kebede | 87.5% | 1.54 | October 2026 |
| Tony Tran | 69.0% | 2.66 | October 2026 |
| Andres Munoz | 75.3% | 1.96 | October 2026 |
| Errol Fernandes | 82.3% | 1.61 | October 2026 |
| Brian Turner | 81.9% | 2.05 | October 2026 |
| Mounir S Amer | 87.6% | 1.56 | August 2026 |
| Bo Bin Jang | 86.3% | 1.65 | October 2026 |
| Alexander Belousov | 72.4% | 2.22 | October 2026 |
| Thanhha Pham | 77.9% | 1.60 | October 2026 |
| Bradley K. Smith | 75.5% | 1.83 | October 2026 |
| Michele Fan | 81.0% | 2.13 | October 2026 |
| Marvin Payen | 62.1% | 1.92 | October 2026 |
| Amar Movva | 65.8% | 2.12 | October 2026 |
| Mohammad Choudhry | 40.0% | 2.07 | October 2026 |
| Pratiksha J Lohakare | 80.0% | 2.56 | October 2026 |
| Zhijun Xu | 76.9% | 2.78 | October 2026 |
| Nicholas B. Michaud | 100.0% | 1.93 | October 2026 |
Examiner distribution
- Median grant ratio
- 80.0%
- Middle 50% of grant ratios
- 73.8%–83.5%
- Median office actions / grant
- 1.95
- Middle 50% of office actions / grant
- 1.63–2.13
Active examiners with at least 20 applications.
Other associated examiners
Examiners without recent activity.
| David E Graybill | 52.5% | 2.05 | June 2021 Appears inactive |
|---|---|---|---|
| Maria Ligai | 68.9% | 2.04 | March 2018 Appears inactive |
| Johannes P. Mondt | 70.4% | 2.58 | March 2018 Appears inactive |
| Dilinh Nguyen | 84.1% | 2.18 | March 2025 Appears inactive |
| Mark A. Laurenzi Iii | 71.9% | 2.00 | July 2026 Potentially inactive |
| Thanh V. Pham | 65.7% | 1.85 | October 2017 Appears inactive |
| Monica Lewis | 50.0% | 1.26 | June 2026 Potentially inactive |
| Alexander Belousov | 0.0% | N/A | September 2021 Appears inactive |
Based on available public USPTO records; may be incomplete.